touchLearning Activities
Education, Conference Coverage and Articles
A new Endocrine Society Clinical Practice Guideline recommends a more selective approach to diagnostic testing and treatment for children with suspected central precocious puberty (CPP), particularly in children whose early pubertal signs are mild or slowly progressive.1,2
Adults with prediabetes who received an intensive lifestyle intervention in the Diabetes Prevention Program were less likely to develop multiple chronic conditions over long-term follow-up than those assigned to placebo, according to an analysis published in JAMA.1 A similar reduction was not observed with metformin.
Three-year extension data suggest sustained growth improvements with vosoritide in children with hypochondroplasia, although findings should be interpreted in the context of a small, responder-enriched extension population.
Dr Eric Ravussin discusses REDEFINE 1 findings from ECO 2026, highlighting improvements in physical function and preserved functional strength despite substantial weight loss with the GLP-1/amylin agonist combination CagriSema.
The FDA has granted accelerated approval to teplizumab-mzwv to delay the decline in endogenous insulin production in children aged 8–17 years recently diagnosed with stage 3 type 1 diabetes (T1D).1 The approval marks the first disease-modifying treatment option for this population.
New interim data from OUTSTEP 1 reveal high levels of patient satisfaction with injectable semaglutide and underscore the importance of understanding patient experiences beyond clinical trials. “While still endorsing the ‘my responsibility only’ narrative, we are learning that a new attitude ...
Following ECO 2026, Dr Line Kristin Johnson discusses new evidence supporting structured rapid weight loss programmes, highlighting their potential to improve long-term weight loss, achieve risk-reduction targets and reshape obesity management.
At EASL 2026, Manal Abdelmalek discusses a post hoc ESSENCE trial analysis showing semaglutide provides consistent liver health benefits in MASH, regardless of menopausal status, age or sex.
At EASL 2026, Lung-Yi Loey Mak discusses evolving hepatitis B management in young patients, including early treatment strategies, perinatal prevention, global practice variations and emerging approaches to cancer risk prediction.
Dr Laurence Dobbie discusses a new European consensus statement highlighting the nutritional, functional and psychological considerations needed to support safe, effective and equitable use of incretin-based therapies in obesity management.
Professor Angus Forbes discusses research presented at Diabetes UK 2026 on stigma in gestational diabetes, highlighting its impact on psychological wellbeing, engagement with care and opportunities to improve patient support.
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your work, and what building that bench can mean for your career, and the life you build alongside it.
In this interview, Diana Isaacs shares her highlights from the 2026 AACE Annual Meeting, discussing key advances in diabetes management, obesity treatment and diabetes technology, alongside emerging priorities for future endocrinology research and guideline development.
DiaLeb’s annual panel explored women’s diabetes care, highlighting lived experience, visibility, and the need to move beyond tokenism toward genuine co-creation in shaping more equitable, responsive health systems.
Dr Ahmed Iqbal joins the touchREVIEWS in Endocrinology Editorial Board, bringing expertise in hypoglycaemia and personalized diabetes care.
New data presented at the Advanced Technologies & Treatments for Diabetes 2026 highlight a shift in diabetes care beyond glucose control alone. Emerging evidence supports the growing role of incretin-based therapies such as semaglutide, alongside advances in continuous glucose monitoring systems including Dexcom G7 and Freestyle Libre 3. Together, these innovations demonstrate meaningful improvements in glycemic outcomes, cardiometabolic risk, and patient behaviors, signaling a move toward more personalized, integrated approaches to diabetes management across both type 1 and type 2 diabetes.
touchENDOCRINOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
